

Anti-C1S (Sutimlimab), Humanized Antibody

08/20

CATALOG NO.: A2205-100 (100 µg)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a humanized IgG4 monoclonal antibody that targets human complement factor C1s. C1s is a serine protease that is part of the C1 complex which contains a pattern recognition receptor (C1q) and a C1s activating serine protease (C1r). Activation of C1 complex results in the formation of C3 convertase which cleaves to form C3a and C3b. Chronic activation of the complement system results in extravascular hemolysis which is responsible for the pathophysiology of anemia in cold agglutinin disease (CAD). Binding of the antibody to complement factor C1s prevents the activation of the complement system and subsequent hemolysis. However, the antibody does not affect immune surveillance functions of alternative and lectin complement pathways. Currently, the original drug received priority review status from the FDA to treat hemolysis in adult patients suffering from cold agglutinin disease (CAD).

ALTERNATE NAMES: BIVV 009, BIVV-009, BIVV009, IPN 009, IPN-009, IPN009, TNT009, EDSPD2

ANTIBODY TYPE: Monoclonal

CONCENTRATION: 1 mg/ml

HOST/ISOTYPE: Recombinant / IgG4, kappa

SOURCE: CHO cells

IMMUNOGEN: Human C1S

CAS NUMBER: 2049079-64-1

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

STORAGE CONDITIONS: Store at -80°C

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-Flavivirus group antigen, Human IgG1 Antibody (A1102)

Anti-RSV (Felvizumab), Human IgG1 Antibody (A1446)

Anti-RSV (Palivizumab), Humanized Antibody (A2166)

Anti-IL-6 (Siltuximab), Chimeric Antibody (A2143)

Anti-C5 (Eculizumab), Humanized Antibody (A2138)

FOR RESEARCH USE ONLY! Not to be used on humans.